BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Gets Price Target Reduction from Morgan Stanley

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective reduced by equities research analysts at Morgan Stanley from $122.00 to $119.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley‘s price objective indicates a potential upside of 116.79% from the company’s current price.

Other analysts also recently issued research reports about the stock. Jefferies Financial Group increased their target price on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a report on Monday, August 31st. Stifel Nicolaus reduced their price objective on shares of BioMarin Pharmaceutical from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Tuesday. Piper Sandler upped their price objective on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 1st. HC Wainwright reissued a “neutral” rating and set a $60.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday. Finally, Royal Bank Of Canada dropped their target price on shares of BioMarin Pharmaceutical from $62.00 to $60.00 and set a “sector perform” rating on the stock in a research report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $87.96.

BioMarin Pharmaceutical Stock Down 4.4%

Shares of BioMarin Pharmaceutical stock traded down $2.55 during trading on Tuesday, reaching $54.89. 1,587,979 shares of the company traded hands, compared to its average volume of 2,110,677. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The firm has a market capitalization of $10.63 billion, a PE ratio of 148.55, a P/E/G ratio of 0.61 and a beta of 0.22. The company has a 50 day moving average price of $60.43 and a 200-day moving average price of $58.46. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.31. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the company posted $0.12 earnings per share. The company’s quarterly revenue was up 32.0% on a year-over-year basis. As a group, equities research analysts expect that BioMarin Pharmaceutical will post 2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC grew its stake in BioMarin Pharmaceutical by 23.4% in the 3rd quarter. Kestra Advisory Services LLC now owns 4,520 shares of the biotechnology company’s stock valued at $271,000 after buying an additional 857 shares in the last quarter. Bfsg LLC purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter worth $1,052,000. Oregon Public Employees Retirement Fund lifted its position in shares of BioMarin Pharmaceutical by 0.5% during the third quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock worth $2,407,000 after acquiring an additional 200 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of BioMarin Pharmaceutical in the third quarter worth $186,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of BioMarin Pharmaceutical in the third quarter worth $705,000. 98.71% of the stock is currently owned by institutional investors.

Key Stories Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with expectations. Adjusted EPS was $0.23, well above the consensus estimate for a loss of roughly $0.08–$0.09. Growth was led by a 44% increase in metabolic-condition revenue and a 12% rise in skeletal-condition revenue. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company added a new investigational Fabry disease asset to its clinical portfolio and reported a May 30, 2027 PDUFA action date for VOXZOGO in hypochondroplasia, supporting BioMarin’s longer-term growth story.
• Positive Sentiment: Options activity was notably bullish, with traders purchasing 3,961 call options—about 228% above typical call volume—suggesting increased speculative interest in a potential rebound.
• Neutral Sentiment: Analyst opinion remains mixed. Citi reiterated a Buy rating, while Royal Bank of Canada maintained a Sector Perform rating, indicating that near-term execution concerns are balanced against BioMarin’s pipeline potential.
• Negative Sentiment: BioMarin lowered its 2026 adjusted EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and issued revenue guidance of $3.8 billion–$3.9 billion versus the $3.9 billion consensus. Management cited order-timing uncertainty and charges related to two acquired in-process research programs. BioMarin Q3 2026 Results and Guidance
• Negative Sentiment: Royal Bank of Canada lowered its BMRN price target from $62 to $60 while retaining its Sector Perform rating, reinforcing investor concerns about limited near-term upside.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.